Stockpolly
Search
ALMS · NASDAQ · Biotechnology

Alumis (ALMS)

Develops oral TYK2 therapies for immune-mediated diseases in the body and brain.

$10.28
Pre-market−0.04 (−0.39%)
At close$10.32(+8.98%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000001732222
Cost of revenue001001000010
Gross profit00−100−11732212
4440475698981191431179899151
Research & development3835414988869710998838185
66681111222120161923
General & administrative6668110222120161923
Other expenses00000001300042
Operating income−44−40−48−56−98−99−102−141−115−96−98−149
01−205431915455
Interest income111254335455
Other non-operating income0−120−5−4−3−20−5−4−50
Income before tax−43−39−50−57−93−95−9951−111−93−93−144
Income tax expense0000000−9000−2
Net income from continuing operations−43−39−50−57−93−95−9959−111−93−93−142
Net income−43−39−50−57−93−95−9959−111−93−93−142
EPS, basic−$1.13−$0.76−$0.96−$1.04−$1.73−$1.74−$1.82$0.78−$1.06−$0.89−$0.74−$1.11
EPS, diluted−$1.13−$0.76−$0.96−$1.04−$1.73−$1.74−$1.82$0.77−$1.06−$0.89−$0.74−$1.11
Weighted average shares, basic3852525454545476104105125128
Weighted average shares, diluted3852525454545477104105125128
EBITDA−43−39−49−56−92−94−98−120−110−92−92−149
Depreciation & amortization011111111110
EBIT−43−39−50−57−93−95−99−121−111−93−93−149